CD4 and neoplasm: CXCL9, CXCL10, and CXCL11 were found to recruit CD4+ and CD8+ lymphocytes [18–20], while CXCL13 could specifically attract T regulatory and Th2 lymphocytes into the tumour microenvironment [21].